Skip to Content

Bausch & Lomb Corp

BLCO: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$84.00KchvlqDsgkpgf

Bausch & Lomb Earnings: Solid Quarter on Broad-Based Growth but Cutting FVE After Updating Drivers

Narrow-moat Bausch & Lomb reported first-quarter earnings that came largely in line our expectations. Total sales of $1.0 billion were up 18% year over year from strong demand in consumer products and a substantial sales hike in the ophthalmic pharmaceuticals segment thanks to Xiidra and Miebo contributions. Despite unfavorable foreign exchange, which created about $20 million in headwinds, strong execution across categories made for a solid quarter.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BLCO so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center